The Week in Review in Drug Pricing

Former CMS Administrator Andy Slavitt summed up the insulin crisis in eight numbers:
 
3
6
21
39
275
4,000 - 6,000
30 million
 
Read it all here and welcome to the week in review in prescription drug pricing!
 
1. The Price is Not Right

  • A coalition of attorneys general from more than 40 states is suing generic drug makers for price collusion in one of the biggest alleged industry-wide price fixing schemes in U.S history. — (CBS 60 Minutes)


2. #GlaxoSmithLies

  • GlaxoSmithKline has relied on a handful of abusive tactics to keep profit margins high while raising prices. In return, patients with asthma who need blockbusters like Advair are in dire straits. —  (Patients For Affordable Drugs)


3.You get a yacht!

  • Healthcare CEOs made $2.6 billion last year. The highest salary went to a pharma executive. — (Axios)


4.All the excuses

  • Research and development is often the go-to defense when pharma is questioned on mile-high prices, but  a new study says it is nothing but spin. — (The Fiscal Times)

 
5. It has to end

  • We need legislation to stop deals for delay and patent thickets, AbbVie’s monopolistic bread and butter. — (STAT)